Latest Administration News

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

VanEck Investments Limited has released a replacement Product Disclosure Statement for its VanEck Bentham Global Capital Securities Active ETF (ASX, GCAP), outlining an actively managed strategy focused on global subordinated debt securities with income and diversification benefits.

Dateline Resources secures high-level U.S. government endorsement for its Colosseum Rare Earths Project, highlighting its strategic role in domestic critical minerals supply. The project’s significant gold resources and rare earth potential position it as a key player in America’s mineral independence efforts.

Alara Resources has announced a private placement to raise A$3.4 million aimed at repaying a significant portion of its Trafigura loan, subject to shareholder approval. The move underscores strong backing from major shareholders and a strategic focus on financial stability.

Dateline Resources secures high-level U.S. government backing to accelerate its Colosseum Rare Earths Project in California, highlighting its strategic role in domestic critical minerals supply.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Centrex Limited’s creditors are set to decide on a proposed restructuring plan by PRL Global Limited that could reshape the company’s future and creditor recoveries.

AnteoTech Ltd has completed a strategic review that refocuses its business on commercialising existing products, delivering $1.6 million in annual cost savings and expanding its sales pipeline in battery and life sciences markets.

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Vection Technologies has launched its Algho AI Sign Language solution on Amazon Web Services Marketplace, targeting enhanced accessibility across Europe. Early contracts signal strong market interest in AI-driven communication tools for the Deaf and hard-of-hearing community.